NovaBridge Biosciences (NBP)
NASDAQ:NBP
Want to see NBP full AI Analyst Report?
NBP Stock Chart & Stats
$2.70
--
Market closed
$2.70
--
Day’s Range― - ―
52-Week Range$0.81 - $6.79
Previous CloseN/A
VolumeN/A
Average Volume (3M)925.28K
Market Cap
$271.15M
Enterprise Value$1.64B
Total Cash (Recent Filing)$210.84M
Total Debt (Recent Filing)$3.07M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding115,381,690
10 Day Avg. Volume859,716
30 Day Avg. Volume925,284
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)11.54
Price to Sales (P/S)0.00
P/FCF Ratio-129.35
Enterprise Value/Market Cap6.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.08K
Enterprise Value/Ebitda-11.15
Forecast
1Y Price Target
$9.00Price Target Upside233.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.15
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Runway / LiquidityA substantial year-end cash balance provides multi-year runway to fund mid-stage trials and platform development, materially reducing near-term financing risk. This enables NovaBridge to advance givastomig and VIS-101 through registrational-enabling studies and preserves optionality for partnering or out-licensing.
Regulatory Pathway For Lead Oncology AssetFormal FDA feedback supporting an accelerated approval pathway is a structural competitive advantage: it can shorten time to market if later data confirm benefit, concentrate development resources on a registrational design, and increase the asset's partnerability and commercial upside relative to peers.
Platform Strategy / Mid‑stage FocusA clear hub-and-spoke business model focused on clinical de-risking leverages NovaBridge's deal-making and regional network, allowing capital-efficient value creation at proof-of-concept. This structural strategy supports repeatable partnering, spin-outs or licensing as assets mature, enhancing long-term growth pathways.
Bears Say
Persistent Cash BurnMulti-year negative operating and free cash flows indicate structural cash burn that can erode flexibility if clinical timelines slip or costs rise. Even with current cash, sustained negative cash generation raises dependency on financing or partnerships to complete pivotal trials and commercialize assets.
Minimal Recent RevenueA near-zero revenue base means the company remains pre-commercial and reliant on pipeline milestones and financing. Lack of recurring product revenue increases sensitivity to clinical or regulatory setbacks and limits self-sustaining growth until one or more assets reach commercialization or generate partner/license income.
Sustained Losses And Equity ErosionOngoing material losses have eroded equity and asset base, reflected in contracting balance-sheet size and negative returns. This weakens financial resilience over time, reducing cushion for development setbacks and potentially diluting shareholders if additional capital is required to sustain the clinical agenda.
NovaBridge Biosciences News
NBP FAQ
What was NovaBridge Biosciences’s price range in the past 12 months?
NovaBridge Biosciences lowest stock price was $0.81 and its highest was $6.79 in the past 12 months.
What is NovaBridge Biosciences’s market cap?
NovaBridge Biosciences’s market cap is $271.15M.
When is NovaBridge Biosciences’s upcoming earnings report date?
NovaBridge Biosciences’s upcoming earnings report date is May 14, 2026 which is in 14 days.
How were NovaBridge Biosciences’s earnings last quarter?
NovaBridge Biosciences released its earnings results on Apr 07, 2026. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.11.
Is NovaBridge Biosciences overvalued?
According to Wall Street analysts NovaBridge Biosciences’s price is currently Undervalued.
Does NovaBridge Biosciences pay dividends?
NovaBridge Biosciences does not currently pay dividends.
What is NovaBridge Biosciences’s EPS estimate?
NovaBridge Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NovaBridge Biosciences have?
NovaBridge Biosciences has 115,381,690 shares outstanding.
What happened to NovaBridge Biosciences’s price movement after its last earnings report?
NovaBridge Biosciences reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went down -1.21%.
Which hedge fund is a major shareholder of NovaBridge Biosciences?
Currently, no hedge funds are holding shares in NBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NovaBridge Biosciences Stock Smart Score
Company Description
NovaBridge Biosciences
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
NBP Stock 12 Month Forecast
Average Price Target
$9.00
▲(233.33% Upside)
Ownership Overview
0.20% Insiders
0.07% Mutual Funds
0.11% Other Institutional Investors
98.67% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---